Company / Depreciation & Amortization
Charles River Laboratories Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$403.3M
FY2025
5-year range
$198.1M / $403.3M
FY2021-FY2025
Trend
+11.5%
vs FY2024
Sector context
#30 of 147
Health Care
What the data says
Charles River Laboratories's depreciation & amortization of $403M is higher than 80% of companies in the Health Care sector (FY2025). Depreciation & Amortization has increased for 6 consecutive years, from $131M in FY2019 to $403M in FY2025.
Based on SEC 10-K filings.
$403M in FY2025 with a 5-year CAGR of +20.0%. Top quartile in the Health Care sector.
Increased from $266M to $403M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +19.7%
- 5-Year CAGR
- +20.0%
- 10-Year CAGR
- -
Sector benchmark
+19.1% above sector average
Key checks
Key Insights
- Charles River Laboratories's depreciation & amortization has grown for 6 consecutive years.
- 5-year CAGR of +20.0%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 11.5% year-over-year.
- Ranks #30 out of 147 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $403.3M | +11.5% |
| FY2024 | $361.7M | +36.2% |
| FY2023 | $265.5M | +13.0% |
| FY2022 | $234.9M | +18.6% |
| FY2021 | $198.1M | +22.4% |
| FY2020 | $161.8M | +23.3% |
| FY2019 | $131.2M | -18.9% |
| FY2018 | $161.8M | +23.3% |
| FY2017 | $131.2M | +3.6% |
| FY2016 | $126.7M | +31.1% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026